This article provides a broad frame of reference for analyzing most favoured nation (MNF) clauses, based on the case law and practice of the European courts and the European Commission. To read the article, click the link below.
What’s 340B? An economist’s view of the recent wave of 340B litigation
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing...
